Cowen & Co. Downgrades CytomX Therapeutics to Market Perform

Cowen & Co. analyst Boris Peaker downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Market Perform.

Cowen & Co. analyst Boris Peaker downgrades CytomX Therapeutics (NASDAQ:CTMX) from Outperform to Market Perform.

Total
0
Shares
Related Posts